Citius PharmaceuticalsCTXR
13F holders, Q3 2025 (September 30)34holders +3
8new positions
5sold out
$1.24avg. 13F price*
At the end of Q3 2025, 34 institutions reported holding Citius Pharmaceuticals Inc. (CTXR) in their 13F filings, up 3 from Q2 2025. 8 opened new positions and 5 sold out. The largest holders were Vanguard Group Inc. ($206K), Geode Capital Management, LLC ($149K) and BlackRock, Inc. ($87K).
- Company
- Citius Pharmaceuticals Inc.
- CUSIP
- 17322U306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $38K |
| Exits | 5 | $282K |
All 13F filers, Q2 2025 → Q3 2025: 217,888 shares bought and 522,246 shares sold, net −304,358 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 34 holders
| Vanguard Group Inc. | 0.00% | Add +107.7% | 166,390 | $206K |
| Geode Capital Management, LLC | 0.00% | Add +57.4% | 119,771 | $149K |
| BlackRock, Inc. | 0.00% | No change | 69,851 | $87K |
| Susquehanna International Group, LLP | 0.00% | Add +239.4% | 48,186 | $60K |
| Northern Trust Corp. | 0.00% | Add +88.0% | 27,025 | $34K |
| UBS Group AG | 0.00% | Reduce -86.6% | 25,913 | $32K |
| NewEdge Advisors, LLC | 0.00% | Add +1.6% | 25,400 | $31K |
| State Street Corp. | 0.00% | No change | 23,271 | $29K |
| Two Sigma Investments, LP | 0.00% | Add +69.4% | 21,803 | $27K |
| Arkadios Wealth Advisors | 0.00% | No change | 20,000 | $25K |
| Jane Street Group, LLC | 0.00% | New | 18,885 | $23K |
| XTX Topco Ltd | 0.00% | Reduce -21.0% | 15,922 | $20K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | Reduce -94.5% | 10,044 | $12K |
| Simplex Trading, LLC | 0.00% | New | 9,556 | $11K |
| IFP Advisors, Inc | 0.00% | No change | 7,083 | $9K |
| Chelsea Counsel Co. | 0.00% | No change | 4,626 | $6K |
| SBI Securities Co., Ltd. | 0.00% | Add +0.1% | 4,020 | $5K |
| Citigroup Inc. | 0.00% | New | 1,617 | $2K |
| Osaic Holdings, Inc. | 0.00% | Reduce -11.9% | 1,487 | $2K |
| Legacy Wealth Managment, LLC | 0.00% | New | 930 | $1K |
| Luminist Capital LLC | 0.00% | No change | 435 | $596 |
| Bank of America Corp. | 0.00% | Add +11.9% | 422 | $523 |
| Morgan Stanley | 0.00% | Add +578.3% | 407 | $504 |
| Farther Finance Advisors, LLC | 0.00% | New | 343 | $425 |
| Murphy & Mullick Capital Management Corp | 0.00% | No change | 160 | $251 |
| Princeton Global Asset Management LLC | 0.00% | No change | 160 | $198 |
| JPMorgan Chase & Co. | 0.00% | No change | 120 | $149 |
| Smallwood Wealth Investment Management, LLC | 0.00% | No change | 120 | $148 |
| Quent Capital, LLC | 0.00% | New | 108 | $134 |
| BNP Paribas Financial Markets | 0.00% | No change | 107 | $133 |
| Arax Advisory Partners | 0.00% | New | 84 | $104 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 80 | $99 |
| Fairscale Capital, LLC | 0.00% | No change | 42 | $52 |
| Wells Fargo & Company | 0.00% | New | 40 | $50 |
"% of holder's portfolio" is CTXR's weight in each manager's 13F, not the share of Citius Pharmaceuticals Inc. the manager owns.